文献速递腹部泌尿生殖CT

结直肠癌患者奥沙利铂所致肝损伤的长期随访

Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer.
PubMed 文献 · Br J Radiol · 2021-06-16

回顾性纳入2013年1月至2014年12月间接受手术及奥沙利铂为基础化疗的356例结直肠癌患者,复查腹部CT及实验室指标。化疗期间90.2%(321/356)出现肝实质不均质,62.4%(225/356)脾脏增大,23.9%(85/356)出现急性门体分流,仅1.4%(5/356)在化疗结束后持续存在慢性门静脉高压;部分实验室指标未恢复至化疗前水平。

要点

  • 化疗期间肝实质不均质发生率90.2%(321/356),脾大62.4%(225/356),急性门体分流23.9%(85/356)。
  • 化疗结束后除1.4%(5/356)持续慢性门静脉高压外,上述影像表现多可恢复。
  • AST、ALT、总胆红素在化疗期间升高、血小板降低,化疗结束后未完全恢复至化疗前水平。

核心结论

  • 多数奥沙利铂所致肝损伤相关改变在化疗结束后可恢复至正常范围,但部分指标未恢复至治疗前水平,少数患者发生慢性门静脉高压。

研究设计与样本

  • 回顾性纳入2013年1月至2014年12月间接受手术及奥沙利铂为基础化疗的结直肠癌患者356例,于化疗前(基线)、化疗期间及化疗后复查腹部CT和实验室指标(AST、ALT、白蛋白、总胆红素、血小板计数)。

关键影像表现/征象

  • 化疗期间90.2%(321/356)患者出现肝实质不均质。
  • 化疗期间62.4%(225/356)患者脾脏增大。
  • 化疗期间23.9%(85/356)患者出现急性门体分流。
  • 化疗结束后上述表现多可恢复,仅1.4%(5/356)患者持续存在慢性门静脉高压。

诊断标准与关键数值

  • 肝实质不均质发生率90.2%(321/356)。
  • 脾脏增大发生率62.4%(225/356)。
  • 急性门体分流发生率23.9%(85/356)。
  • 慢性门静脉高压持续存在率1.4%(5/356)。

临床应用与阅片要点

  • 化疗期间及化疗后复查腹部CT时,应注意评估肝实质不均质、脾脏增大及门体分流等征象。
  • 化疗结束后影像表现多可恢复,但需关注少数持续慢性门静脉高压及门体分流相关并发症(如静脉曲张出血)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To report the long-term follow-up data including computed tomography (CT) findings of oxaliplatin-induced liver damage in patients with colorectal cancer.

METHODS: Three hundred and fifty-six patients who underwent surgery followed by oxaliplatin-based chemotherapy (OBC) for colorectal cancer between January 2013 and December 2014 were included. Abdominal CT images and laboratory results (serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, total bilirubin, and platelet counts) were reviewed immediately before (as baseline), during, and after adjuvant OBC. Abdominal CT images were reviewed to assess the heterogeneous liver parenchyma, increase in size of the spleen, development of acute portosystemic shunts during OBC, and imaging findings of chronic portal hypertension.

RESULTS: During OBC, 90.2% (321/356) of the patients developed parenchymal heterogeneity. Increase in the spleen size during the OBC period was seen in 62.4% (225/356) of patients. The overall rate of development of acute portosystemic shunts during OBC was 23.9% (85/356). These findings were resolved after cessation of OBC except in 1.4% (5/356) of the patients in whom chronic portal hypertension persisted even after completion of OBC. Serum AST, ALT, and total bilirubin levels increased and platelet counts decreased during OBC and returned to normal after completion of OBC; however, they did not reach the pre-OBC levels.

CONCLUSION: Although most changes associated with liver damage reversed to normal range after completion of OBC, some parameters did not reverse to the pretreatment level, and chronic portal hypertension developed in a small number of patients.

ADVANCES IN KNOWLEDGE: Chronic, persistent oxaliplatin-induced liver damage was not an infrequent complication after oxaliplatin-based chemotherapy for patients with colorectal cancer. It may cause non-cirrhotic portal hypertension and associated complications such as variceal bleeding.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Cha DI, Song KD, Ha SY, et al. Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer. Br J Radiol. 2021. PMID: 34133224. doi:10.1259/bjr.20210352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。